Publication: A case series of refractory cutaneous sarcoidosis successfully treated with infliximab
Issued Date
2012-12-20
Resource Type
ISSN
21909172
Other identifier(s)
2-s2.0-84871160440
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Dermatology and Therapy. Vol.2, No.1 (2012), 1-9
Suggested Citation
Papapit Tuchinda, Matthew Bremmer, Anthony A. Gaspari A case series of refractory cutaneous sarcoidosis successfully treated with infliximab. Dermatology and Therapy. Vol.2, No.1 (2012), 1-9. doi:10.1007/s13555-012-0011-9 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/14412
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A case series of refractory cutaneous sarcoidosis successfully treated with infliximab
Other Contributor(s)
Abstract
Introduction: Sarcoidosis is a systemic granulomatous disease of unknown cause. The management of sarcoidosis remains problematic. Systemic and topical corticosteroids are the mainstay of therapy but may cause unacceptable side effects. Biologic therapies, such as infliximab, have recently beenproposed asanother treatment option for cutaneous sarcoidosis. Case Report: The authors describe three patients who were diagnosed with cutaneous sarcoidosis with systemic involvement. All of the patients were refractory to conventional therapies but responded to infliximab therapy. Conclusion: Infliximab is an alternative medication for refractory sarcoidosis that has a relatively benign side-effect profile. However, definite indications, dosage, interval, and duration of treatment for cutaneous sarcoidosis are not firmly established. © The Author(s) 2012.